ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3021-St-Albans-Western-Health-Sunshine-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
33
trial(s) found.
NCT07391670
Advanced
Phase 1
Not yet recruiting
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours (
IMFINZI-subQ
)
anti-PD-L1 monoclonal antibody
Solid tumour
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07291037
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung17
)
anti-Trop2 antibody-drug conjugate
taxane
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07218380
Advanced
Phase 3
Recruiting
FORAGER-2
: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
FGFR3 inhibitor
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
placebo
Bladder cancer
Cancer
Carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07155187
Advanced
Phase 2 / Phase 3
Recruiting
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI (
M25-713
)
anti-cMET antibody-drug conjugate
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT07062965
Advanced
Phase 3
Recruiting
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy (
C4551002
)
KAT6A/B inhibitor
KAT6 inhibitor
selective estrogen receptor degrader
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06989437
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma (
C3651021
)
anti-GDF15 monoclonal antibody
placebo
Pancreatic adenocarcinoma
NSW
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06982521
Advanced
Phase 3
Recruiting
A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor (
ReDiscover-2
)
PI3K alpha inhibitor,allosteric,mutant-selective
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
Cancer
HER2-negative breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
NCT06966453
Advanced
Phase 1 / Phase 2
Recruiting
A PHASE 1b/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER (
C5731006
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06892548
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer (
BNT324-01
)
anti-B7H3 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06756932
Advanced
Phase 1
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer (
BGB-21447-102
)
Bcl2 inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2830 - Dubbo - Dubbo Base Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06534983
Curative
Phase 2
Recruiting
A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma (
IMCODE004
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
personalized cancer vaccine
Urothelial carcinoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06360354
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion (
MTAPESTRY-103
)
PRMT5 inhibitor,MTA-co-operative
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06203210
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (
IDeate-Lung02
)
anti-B7H3 antibody-drug conjugate
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06074588
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (
2870-004
)
anti-Trop2 antibody-drug conjugate
antimetabolite
taxane
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
NCT06065748
Curative
Phase 3
Recruiting
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy (
CO44657
)
selective estrogen receptor degrader
ER-positive HER2-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NA
NA
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05947851
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
MK-1026-010--1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05671510
Advanced
Phase 3
Recruiting
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors (
PRESERVE-003
)
anti-CTLA4 monoclonal antibody
taxane
Non-small cell lung cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05267626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (
CP-AU-007-01
)
anti-IL-2 monoclonal antibody
Cancer
Cutaneous melanoma
Non-small cell lung cancer
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05254743
Haem
Phase 3
Recruiting
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BRUIN-CLL-314
)
BTK inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Small Lymphocytic Lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05222087
Radonc
Phase 1
Recruiting
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer. A Pilot Study (
PRIME-LUNG
)
radiotherapy
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
NCT04606446
Advanced
Phase 1
Recruiting
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (
KAT6
)
KAT6A/B inhibitor
KAT6 inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02960022
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (
9785-CL-0123
)
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621001198819
Radonc
Not Applicable
Recruiting
A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (
RESOLUTE
)
Radiotherapy
cancer therapy
Colorectal cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3677 - Wangaratta - Northeast Health Wangaratta
NCT05852691
Advanced
Phase 2
paused
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (
CO44194
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
taxane
Breast cancer
VIC
3021 - St Albans - Western Health - Sunshine Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (31)
Not yet recruiting (1)
paused (1)
Recruitment Country and State
VIC (33)
NSW (26)
SA (20)
QLD (19)
WA (12)
NZ (5)
TAS (3)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (3)
Phase 2 (4)
Phase 2 / Phase 3 (4)
Phase 3 (16)
Trial Type
Advanced (27)
Curative (2)
Haem (2)
Radonc (2)
Cancer Therapy Class
PD-1/PD-L1
33%
PD-L1
21%
PD-1
18%
oestrogen axis
18%
ER
15%
VEGFA
12%
VEGF
9%
ERBB2
9%
CDK4
9%
CTLA4
6%
Trop2
6%
MET
6%
KAT6A
6%
B7H3
6%
Bcl2
6%
CDK4 selective
6%
CDK6
6%
BTK
6%
LAG3
6%
VEGFR1
3%
VEGFR2
3%
VEGFR3
3%
FGFR3
3%
Nectin4
3%
mTOR
3%
mTORC1
3%
GDF15
3%
AKT
3%
PI3Kalpha
3%
EGFR
3%
PRMT5
3%
LHRH
3%
CD20
3%
IL-2
3%
PARP
3%
AR
3%
CYP17A1
3%
GnRH
3%
androgen axis
3%
Facility
3021 - St Albans - Western Health - Sunshine Hospital (33)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (7)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
3168 - Clayton - Monash Medical Centre (5)
5011 - Woodville South - The Queen Elizabeth Hospital (5)
5042 - Bedford Park - Flinders Medical Centre (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (4)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (4)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (4)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
2217 - Kogarah - St George Hospital (3)
2170 - Liverpool - Liverpool Hospital (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
2076 - Wahroonga - Sydney Adventist Hospital (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (3)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
4215 - Southport - Gold Coast University Hospital (3)
NZ.3210 - Hamilton - Waikato Hospital (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3066 - Epping - Northern Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
7000 - Hobart - ICON Cancer Care Hobart (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
2139 - Concord - Concord Repatriation General Hospital (2)
2500 - Wollongong - Cancer Care Wollongong (2)
4870 - Cairns - Cairns Base Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
2060 - North Sydney - Mater Hospital (2)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (2)
2485 - Tweed Heads - The Tweed Hospital (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3011 - Footscray - Footscray Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
6009 - Nedlands - One Clinical Research (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2830 - Dubbo - Dubbo Base Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NA
NZ.0110 - Whangarei - Whangarei Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4215 - Southport - Tasman Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Respiratory tract cancer
Thoracic cancer
Non-small cell lung cancer
Breast cancer
Gastrointestinal cancer
Urogenital cancer
Colorectal cancer
Lower gastrointestinal cancer
Carcinoma
Breast adenocarcinoma
HER2-negative breast cancer
Haematological malignancy
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
Male genital cancers
Prostate cancer
Bladder cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Colorectal adenocarcinoma
Urothelial carcinoma
Endometrial cancer
Gynaecological cancer
ER-positive HER2-negative breast cancer
ER-positive breast cancer
HR-positive breast cancer
Cutaneous melanoma
Melanoma
Skin cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Germ cell tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy